NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

IO Biotech, Inc. (IOBT) Stock Analysis

IO Biotech, Inc. (IOBT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IOBT

$0.00

+$0.00 (+3.33%)

Last trade May 26, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IOBT with… →

IOBT Key Statistics

As of May 26, 2026
Trading
Open
$0.00
Previous Close
$0.00
Day's Range
0.00–0.00
52-Week Range
0.01–2.79
Volume
194.64K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$3.45M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.23
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−99.74%
Dividend and dates
Avg Volume
21.54M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IOBT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−99.49%
2025−29.43%

As of May 26, 2026.

IOBT Valuation vs Biotechnology Median

Median of 656 stocks
MetricIOBTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values IO Biotech, Inc. (IOBT) at $3.45M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 80 employees.

The most recent close on file for IOBT is $0.00, dated May 26, 2026. That is $0.00 (+3.33%) against the previous close. The 52-week range on file runs from $0.01 to $2.79.

Financial Health

Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.23.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.89. Annualized volatility over the trailing 1 year is 281.96%. Over the trailing twelve months the price has returned −99.74%.

Growth & Income

The record shows no dividend for IOBT.

The record holds one complete calendar year, 2025, which returned −29.43%. 2026 is still running; the price is −99.49% year to date.

Peer Comparison

IO Biotech, Inc. (IOBT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IO Biotech, Inc. IOBT $3.45M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. IO Biotech, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 26, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark. On March 31, 2026, IO Biotech, Inc., along with its affiliate, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Visit website →